This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:Advanced Cell Technology Announces Upcoming Milestones at BIO Europe 2009 2009-11-03 14:13 ET - News Release IND Filing for RPE Program Expected by 2009 Year-end; Company
Announces Plans to File IND For Second Clinical Program During First
Half of 2010
WORCESTER, Mass. -- (Business Wire)
Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTCBB: ACTC)
announced today that its Chief Executive Officer, William Caldwell, IV,
presented at the BIO Europe Conference being held in Vienna, Austria.
The presentation provided a corporate overview and update on the
Company’s plans for its clinical pathway in addition to several other
upcoming developmental milestones, including its planned IND filing with
the FDA for its retinal pigment epithelial (RPE) program prior to the
end of this year, and its goal of becoming one of the first companies to
treat a patient with an embryonic stem cell based therapy, which it
hopes to achieve by the third quarter of 2010. Pending FDA approval, ACT
hopes to commence Phase I clinical trials for its first IND designation
in the summer of 2010, and anticipates filing an IND for an additional
retinal indication in a similar timeframe.
The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. |
Top
Print this Page